Related Experiment Video
Updated: Aug 6, 2026
08:45
Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Published on: July 17, 2020
Possibility to therapeutically exploit RGPR-p117 as a target in cancer cells
1Cancer Biology Program, University of Hawaii Cancer Center, University of Hawaii, Manoa, HI, USA.
Expert Opinion on Therapeutic Targets
|July 17, 2026
Summary
RGPR-p117, a transcription factor, shows promise in cancer therapy by suppressing tumor cell proliferation and enhancing tumor suppressors. Further research is needed to explore its therapeutic potential in clinical settings.
Area of Science:
- Molecular biology
- Cancer research
- Gene therapy
Background:
- RGPR-p117 is a transcription factor that binds to a specific DNA sequence in the regucalcin gene promoter.
- Regucalcin is a known tumor suppressor gene.
- RGPR-p117 plays a role in regulating gene transcription within the cell.
Purpose of the Study:
- To investigate the therapeutic potential of RGPR-p117 in cancer treatment.
- To explore the mechanisms by which RGPR-p117 affects cancer cell proliferation and gene expression.
- To evaluate RGPR-p117 as a target for novel cancer therapies and gene therapy strategies.
Main Methods:
- Identification of RGPR-p117 as a transcription factor.
- Analysis of RGPR-p117's role in gene transcription, specifically the regucalcin gene.
- Assessment of RGPR-p117's effects on cancer cell proliferation and expression of key proteins (e.g., Ras, PI3K, Akt, MAPK, mTOR, p53, Rb, p21) in vitro.
- Investigation of RGPR-p117's nuclear translocation and its impact on gene expression.
Main Results:
- RGPR-p117 enhances transcription of genes with a TTGGC motif, including the tumor suppressor regucalcin gene.
- Overexpression of RGPR-p117 suppresses cancer cell proliferation.
- RGPR-p117 decreases expression of growth-promoting proteins (Ras, PI3K, Akt, MAPK, mTOR) and increases tumor suppressors (p53, Rb, p21).
Conclusions:
- RGPR-p117 demonstrates significant potential as a therapeutic target for cancer treatment.
- Targeting RGPR-p117 nuclear translocation may offer a novel strategy for cancer suppression.
- Further in vivo studies and clinical trials are necessary to validate these in vitro findings and address challenges for clinical application.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...